Synthetic inhibitors of CDKs induce different responses in androgen sensitive and androgen insensitive prostatic cancer cell lines | Zendy

Jana Mad’arová | Zendy

Open Access

Synthetic inhibitors of CDKs induce different responses in androgen sensitive and androgen insensitive prostatic cancer cell lines

Author(s) -

Jana Mad’arová

Publication year - 2002

Publication title -

molecular pathology

Language(s) - English

Resource type - Journals

eISSN - 1472-4154

pISSN - 1366-8714

DOI - 10.1136/mp.55.4.227

Subject(s) - cyclin dependent kinase , lncap , androgen receptor , biology , cell cycle , kinase , cell growth , viability assay , cancer research , cyclin dependent kinase 1 , cell culture , androgen , cancer , cancer cell , microbiology and biotechnology , prostate cancer , cell , biochemistry , genetics , hormone

Because of the high prevalence of prostatic cancer and the limitations of its treatment, enormous effort has been put into the development of new therapeutic modalities. One potential tool is the use of cyclin dependent kinase (CDK) inhibitors, which are based on the trisubstituted derivatives of purine. The aim of this study was to analyse alterations of the regulatory pathways in both androgen sensitive and androgen insensitive prostatic cancer cell lines (LNCaP and DU-145, respectively) after blockage of the cell cycle by the synthetic CDK inhibitors, olomoucine and bohemine.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research